Alvotech
ALVONext catalyst
AVT16 (vedolizumab biosimilar)
Entyvio indication (inflammatory bowel disease)
Get an email about ALVO's next catalysts
Track Alvotech (ALVO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 3 readout).See the timeline
3 upcoming, 0 past
ALVO Earnings Report
EPS Est: $-0.01 | FQ end Sep/2026 | Call: amc
FDA PDUFA Date AVT16 (vedolizumab biosimilar) (standard review)
For Entyvio indication (inflammatory bowel disease). BLA filing. AI-extracted from news: Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchange
SourceAVT29 (proposed aflibercept HD biosimilar) Phase 3 Est. Readout (ALVOEYE-HD)
Estimated primary completion for AVT29 (proposed aflibercept HD biosimilar) trial (NCT07489131) in Diabetic Macular Edema. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
AVT05 (proposed biosimilar to golimumab)
Rheumatoid Arthritis
AVT03
Osteoporosis, Postmenopausal
Stelara
Psoriasis
Adalimumab originator
Plaque Psoriasis
AVT06 (proposed aflibercept biosimilar)
Neovascular (Wet) AMD
AVT29 (proposed aflibercept HD biosimilar)
Diabetic Macular Edema
AVT04
Psoriasis
Adalimumab biosimilar
Plaque Psoriasis
Eylea® (Aflibercept)
Neovascular (Wet) AMD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AVT05 (proposed biosimilar to golimumab) | Phase 3 | Rheumatoid Arthritis | - | - |
AVT03 | Phase 3 | Osteoporosis, Postmenopausal | - | - |
Stelara | Phase 3 | Psoriasis | - | - |
Adalimumab originator | Phase 3 | Plaque Psoriasis | - | - |
AVT06 (proposed aflibercept biosimilar) | Phase 3 | Neovascular (Wet) AMD | - | - |
AVT29 (proposed aflibercept HD biosimilar) | Phase 3 | Diabetic Macular Edema | - | - |
AVT04 | Phase 3 | Psoriasis | - | - |
Adalimumab biosimilar | Phase 3 | Plaque Psoriasis | - | - |
Eylea® (Aflibercept) | Phase 3 | Neovascular (Wet) AMD | - | - |
Frequently asked questions
What is in Alvotech's drug pipeline?→
CatalystAlert tracks 9 drug candidates in Alvotech's (ALVO) pipeline across Phase 3. Its lead program is AVT29 (proposed aflibercept HD biosimilar) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alvotech's next FDA catalyst?→
Alvotech's (ALVO) next tracked catalyst is a PDUFA date expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALVO biotech catalysts?→
Add ALVO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alvotech's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.